You are here

Article info

Article menu
Download PDFPDF
EBM analysis
Mental health
Methylphenidate denied access to the WHO List of Essential Medicines for the second time

Authors

  • Johanne Pereira Ribeiro Psychiatric Research Unit, Psychiatry Region Zealand, Slagelse, Denmark PubMed articlesGoogle scholar articles
  • Charlotte Lunde Centre for Medical Ethics, University of Oslo, Oslo, Norway PubMed articlesGoogle scholar articles
  • Christian Gluud The Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark PubMed articlesGoogle scholar articles
  • Erik Simonsen Psychiatric Research Unit, Psychiatry Region Zealand, Slagelse, Denmark Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Ole Jakob Storebø Psychiatric Research Unit, Psychiatry Region Zealand, Slagelse, Denmark Department of Psychology, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark Department of Child and Adolescent Psychiatry, Psychiatry Region Zealand, Roskilde, Denmark PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Ole Jakob Storebø, Psychiatric Research Unit, Psychiatry Region Zealand, Slagelse 4200, Denmark; ojst{at}regionsjaelland.dk
View Full Text

Citation

Pereira Ribeiro J, Lunde C, Gluud C, et al
Methylphenidate denied access to the WHO List of Essential Medicines for the second time
BMJ Evidence-Based Medicine 2023;28:75-77.

Publication history

  • Accepted January 22, 2022
  • First published February 19, 2022.
Online issue publication 
May 05, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.